ClinicalTrials.gg
CompletedNCT02869438SOLANAUpdated Oct 29, 2019Results posted

A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

A Phase 3 interventional study of Benralizumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 54 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-10-29.

Sponsored by AstraZeneca · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
233
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
10th of 39
233 · median 128
Started
2016
with 4 others
Phase 3
20 of 39
1 open now
Registered
17th of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 10th largest by enrollment, is one of 5 that started in 2016, is one of 20 in phase 3, and was the 17th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the onset and maintenance of effect of benralizumab on lung function, blood eosinophils, asthma control metrics and quality of life during 12-week treatment in patients with uncontrolled, severe asthma with eosinophilic inflammation. A subset of patients will take part in body plethysmography substudy to further investigate the effect on lung function.

03

Conditions studied

  • Asthma

Keywords

  • Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria

  1. Written for study participation must be obtained prior to any study related procedures being performed and according to international guidelines and/or applicable European Union (EU) guidelines.
  2. Female and male aged 18 to 75 years inclusively at the time of Visit 1
  3. Documented current treatment with ICS and LABA for at least 30 days prior to Visit 1. The ICS and LABA can be parts of a combination product or given by separate inhalers. The ICS dose must be greater than or equal to 500 μg/day fluticasone propionate dry powder formulation or equivalent daily. Additional asthma controller medications, eg, oral , long-acting antimuscarinics (LAMAs), LTRAs, theophylline etc. are allowed if they have been used for at least 30 days prior to Visit 1
  4. History of at least 2 asthma exacerbations that required treatment with systemic corticosteroids (intramuscular (IM), intravenous (IV), or oral) in the 12 months prior to Visit 1. For patients receiving corticosteroids as a maintenance therapy, the corticosteroid treatment for the exacerbation is defined as a temporary increase of their maintenance dose.
  5. Pre-bronchodilator (pre-BD) of \< 80% predicted at Visit 2 or Visit 3
  6. ACQ-6 score ≥1.5 at Visit 1
  7. Evidence of asthma as documented by airway reversibility (FEV1 ≥12% and 200 ml) demonstrated at Visit 1, Visit 2 or Visit 3. For patients entering the body plethysmography sub-study, reversibility must be demonstrated at Visit 1 or at Visit 2 only
  8. Peripheral blood eosinophil count of ≥300 cells/μL assessed by central lab at Visit 1
  9. Women of (WOCBP) must use an effective form of confirmed by the Investigator. WOCBP must also have negative serum pregnancy test result on Visit 1.

    Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are . Women will be considered postmenopausal if they have been amenorrheic for 12 months prior to the planned date of randomization without an alternative medical cause. The following agespecific requirements apply:

    • Women \<50 years old are considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone (FSH) levels in the postmenopausal range.
    • Women ≥50 years old are considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment.
  10. All male patients who are sexually active must agree to use a double barrier method of contraception (condom with spermicide) from the first dose of IP until 16 weeks after their last dose
  11. Weight of ≥40 kg

Additional inclusion criteria applicable for the Body Plethysmography substudy 1.Residual volume ≥125% of predicted at Visit 3.

Inclusion criteria at randomization visit

  1. At least 1 of the following within 7 days prior to randomization:

    • Daytime or nighttime asthma symptoms for 2 or more days;
    • Rescue SABA use for 2 or more days;
    • Nighttime awakenings due to asthma at least 1 night during the 7-day period
  2. ACQ >0.75 at Visit 4 prior to randomization.
  3. A negative urine pregnancy test in WOCBP prior to administration of IP

Exclusion criteria

  1. pulmonary disease other than asthma (eg, active lung infection, , bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome)
  2. Life-threatening asthma defined as episodes requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma related syncopal episodes within the 12 months prior to Visit 1.
  3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period
  4. An upper respiratory tract infection or an asthma exacerbation that required treatment with systemic corticosteroids or an increase in regular maintenance dose of OCS during the screening/run-in period prior to randomization Visit 4
  5. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:

    • Affect the safety of the patient throughout the study
    • Influence the findings of the studies or their interpretations
    • Impede the patient's ability to complete the entire duration of study
  6. Known history of allergy or reaction to any component of the product formulation
  7. History of anaphylaxis to any biologic therapy
  8. History of Guillain-Barré syndrome
  9. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with, or has failed to respond to standard of care therapy
  10. Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during screening period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study
  11. Any clinically significant cardiac disease or any (ECG) abnormality obtained during the screening/run-in period, which in the opinion of the Investigator may put the patient at risk or interfere with study assessments
  12. History of alcohol or drug abuse within 12 months prior to the date informed consent is obtained
  13. Positive surface antigen, or virus antibody serology, or a positive medical history for hepatitis B or C. Patients with a history of hepatitis B vaccination without history of hepatitis B are allowed to enroll
  14. A history of known immunodeficiency disorder including a positive (HIV) test
  15. Current smokers or former smokers with a smoking history of ≥10 pack years. A former smoker is defined as a patient who quit smoking at least 6 months prior to Visit 1
  16. Current , or history of malignancy, except for:

    • Patients who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible provided that the patient is in remission and curative therapy was completed at least 12 months prior to the date informed consent was obtained.
    • Patients who have had other malignancies are eligible provided that the patient is in remission and curative therapy was completed at least 5 years prior to the date informed consent was obtained.
  17. Use of medication (including but not limited to: oral corticosteroids [for reasons other than asthma], methotrexate, troleandomycin, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroids or any experimental anti-inflammatory therapy) within 3 months prior to the date informed consent
  18. (ALT) or aspartate aminotransferase (AST) level ≥1.5 times the (ULN) confirmed during screening period
  19. Receipt of immunoglobulin or blood products within 30 days prior to the date informed consent is obtained
  20. Receipt of any marketed (eg, omalizumab, mepolizumab etc.) or investigational biologic within 4 months or 5 half-lives prior to the date informed consent is obtained, whichever is longer
  21. Receipt of 30 days prior to the date of randomization
  22. Receipt of any investigational medication within 30 days or 5 half-lives prior to randomization, whichever is longer
  23. Previously received benralizumab (MEDI-563)
  24. Planned surgical procedures during the conduct of the study
  25. Currently breastfeeding or lactating women
  26. Previous randomization in the present study
  27. Concurrent enrolment in another interventional or post-authorization safety study (PASS).
  28. AstraZeneca staff involved in the planning and/or conduct of the study
  29. Employees of the study center or any other individuals involved with the conduct of the study or immediate family members of such individuals

Exclusion criteria at randomization Visit 4

  1. Greater than/equal to 20% change in mean Pre BD FEV1 value at randomization Visit 4 from the mean pre BD FEV1 calculated from the pre BD FEV1 recorded at Visit 2 and Visit 3
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
233 participants (actual)

Study arms

  • Experimental
    Benralizumab arm

    Benralizumab administered subcutaneously

    Drug: Benralizumab

  • Placebo comparator
    Placebo arm

    Placebo administered subcutaneously

    Other: Placebo

Interventions

  • Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)

  • OtherPlacebo

    Placebo administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)

06

What researchers measure

Primary outcomes

  1. Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in Pre-BD FEV1

    The average over the mean differences between benralizumab and placebo for change from baseline in pre-BD FEV1 is used to determine if the study is positive and to determine maintenance of effect. The first post baseline time point where the p-value for the mean difference between benralizumab and placebo is less than or equal to 0.05 is used to determine time to onset of effect.

    Time frame: From first IP dose to Day 84

  2. Change From Baseline (Visit 4) to End of Treatment Day 84 (Visit 10) in Residual Volume (RV)

    Body plethysmography was performed for sub-study patients. Lung volume subdivisions measures were performed by the investigator or qualified designee according to ATS/ERS guidelines.

    Time frame: From first IP dose to Day 84

Secondary outcomes

  1. Percent Change From Baseline to End of Treatment in Eosinophils Counts

    Percent change from baseline to Day 84

    Time frame: From first IP dose to Day 84

  2. Change From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1

    Post baseline visits include Day 3, Day 7, Day 14, Day 28, Day 56, Day 84. \[Note: Day 28, 56, 84 are presented in the Primary measure.\]

    Time frame: From first IP dose to Day 84

  3. Change From Baseline to Post Baseline for Pre-BD FVC

    Post baseline visits include Day 3, Day 7, Day 14, Day 28, Day 56, and Day 84.

    Time frame: From first IP dose to Day 84

  4. Percentage of Pre-BD FEV1 Responder

    Pre-BD FEV1 responder is defined as change from baseline in FEV1 \>=100 ml

    Time frame: From first IP dose to Day 84

  5. Change From Baseline in ACQ-6

    ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.

    Time frame: From first IP dose to Day 84

  6. Change From Baseline in St. George's Respiratory Questionnaire (SGRQ)

    The SGRQ is designed to measure health impairment in patients with asthma and COPD. It contains two parts: Part 1 (Questions 1 to 8) covers the patients' recollection of their symptoms over a preceding 4 weeks; Part 2, 42 items, relates to the daily activity and psychosocial impacts of the individual's respiratory condition. Total score is presented as a percentage of overall impairment, in which 100 represents the worst possible health status, while 0 indicates the best.

    Time frame: From first IP dose to Day 84

  7. Change From Baseline to End of Treatment in FeNO

    Airway inflammation was evaluated via fractional exhaled nitric oxide (FeNO) measurement.

    Time frame: From first IP dose to Day 84

  8. Change From Baseline to End of Treatment in Total Lung Capacity (TLC) for Sub-study Patients

    Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.

    Time frame: From first IP dose to Day 84

  9. Change From Baseline to End of Treatment in Ratio of Residual Volume (RV) and Total Lung Capacity (TLC) for Sub-study Patients

    Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.

    Time frame: From first IP dose to Day 84

  10. Change From Baseline to End of Treatment in Inspiratory Capacity (IC) for Sub-study Patients

    Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.

    Time frame: From first IP dose to Day 84

  11. Change From Baseline to End of Treatment in Functional Residual Capacity (FRC) for Sub-study Patients

    Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.

    Time frame: From first IP dose to Day 84

  12. Change From Baseline to End of Treatment in Vital Capacity (VC) for Sub-study Patients

    Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.

    Time frame: From first IP dose to Day 84

  13. Duration of IP Administration

    Duration of IP administration is last IP dose date - first IP dose +1.

    Time frame: From first IP to last IP

Other outcomes

  1. Serum Concentration of Benralizumab

    PK sample was collected pre-dose at each visit

    Time frame: From first dose to end of treatment period (Day 84)

  2. PK Parameter of Benralizumab (Cmax)

    PK parameters are derived in patients with at least three qualifiable serum PK concentrations post first dose (collected on Day 3, 7, and either 14, or 28)

    Time frame: First IP dose cycle (ie, data collected on Days 3, 7, 14 and 28)

  3. Anti-drug Antibody Responses

    Anti-drug antibody responses at baseline and post baseline, including nAb responses

    Time frame: From first IP dose to end of treatment period (Day 84)

  4. Change From Baseline to End of Treatment in PGI-S

    The patient global impression of severity (PGI-S) is a single item designed to capture the patient's perception of overall symptom severity at the time of the completion using a 6-point categorical response scale (no symptom \[0\] to very severe symptom \[5\])

    Time frame: From first IP dose to Day 84

  5. Change From Baseline to End of Treatment in CGI-C

    Clinician global impression of change (CGI-C) is used for an overall evaluation of response to treatment. The investigator is asked to rate the degree of change in overall asthma status compare to the start of treatment. A 7-point rating scale is used from 1=very much improved to 7=very much worse.

    Time frame: From first IP dose to Day 84

  6. Change From Baseline to End of Treatment in PGI-C

    Patient global impression of change (PGI-C) is used for an overall evaluation of response to treatment. The patient is asked to rate the degree of change in overall asthma status compare to the start of treatment. A 7-point rating scale is used from 1=very much improved to 7=very much worse.

    Time frame: From first IP dose to Day 84

  7. Change From Baseline to End of Treatment in Specific Airway Resistance (SGaw) for Sub-study Patients

    Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.

    Time frame: From first IP dose to Day 84

  8. Change From Baseline to End of Treatment in Airway Resistance (Raw) for Sub-study Patients

    Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.

    Time frame: From first IP dose to Day 84

07

Results

Posted Oct 7, 2019

Participant flow

Participant flow — Overall Study
MilestoneBenra 30 mgPlacebo
Started118115
Completed115113
Not completed32
Withdrew: Lost to follow-up10
Withdrew: Adverse event10
Withdrew: Withdrawal by subject12

Outcome measures

PrimaryChange From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in Pre-BD FEV1

The average over the mean differences between benralizumab and placebo for change from baseline in pre-BD FEV1 is used to determine if the study is positive and to determine maintenance of effect. The first post baseline time point where the p-value for the mean difference between benralizumab and placebo is less than or equal to 0.05 is used to determine time to onset of effect.

Time frame:
From first IP dose to Day 84
Reported as:
Mean · Liter
Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in Pre-BD FEV1
LiterBenra 30 mgPlacebo
Day 280.21 ± 0.3350.132 ± 0.316
Day 560.22 ± 0.3670.203 ± 0.349
Day 840.209 ± 0.3440.149 ± 0.366
Statistical analysis
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.0707 · Mean difference (final values): 0.077 · 95% CI -0.007 to 0.161For Day 28
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.7747 · Mean difference (final values): 0.013 · 95% CI -0.077 to 0.104For Day 56
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.0969 · Mean difference (final values): 0.079 · 95% CI -0.014 to 0.173For Day 84
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.1558 · Mean difference (final values): 0.057 · 95% CI -0.022 to 0.135For average over Day 28, 56, and 84
PrimaryChange From Baseline (Visit 4) to End of Treatment Day 84 (Visit 10) in Residual Volume (RV)

Body plethysmography was performed for sub-study patients. Lung volume subdivisions measures were performed by the investigator or qualified designee according to ATS/ERS guidelines.

Time frame:
From first IP dose to Day 84
Reported as:
Mean · Liter
Change From Baseline (Visit 4) to End of Treatment Day 84 (Visit 10) in Residual Volume (RV)
LiterBenra 30 mgPlacebo
Change From Baseline (Visit 4) to End of Treatment Day 84 (Visit 10) in Residual Volume (RV)-0.415 ± 0.609-0.208 ± 0.528
Statistical analysis
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.2847 · Mean difference (final values): -0.176 · 95% CI -0.505 to 0.153Model includes covariates of treatment, baseline RV, region, visit, treatment by visit interaction.
SecondaryPercent Change From Baseline to End of Treatment in Eosinophils Counts

Percent change from baseline to Day 84

Time frame:
From first IP dose to Day 84
Reported as:
Mean · Percent change
Percent Change From Baseline to End of Treatment in Eosinophils Counts
Percent changeBenra 30 mgPlacebo
Percent Change From Baseline to End of Treatment in Eosinophils Counts-88.55 (-100 to -12.5)11.55 (-91.4 to 833.3)
Statistical analysis
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -101.0 · 95% CI -118.9 to -83.06Model includes covariates of treatment, baseline eosinophils counts, region, visit, treatment by visit interaction.
SecondaryChange From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1

Post baseline visits include Day 3, Day 7, Day 14, Day 28, Day 56, Day 84. \[Note: Day 28, 56, 84 are presented in the Primary measure.\]

Time frame:
From first IP dose to Day 84
Reported as:
Mean · Liter
Change From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1
LiterBenra 30 mgPlacebo
Day 30.104 ± 0.2230.081 ± 0.269
Day 70.125 ± 0.2290.081 ± 0.263
Day 140.126 ± 0.30.1 ± 0.287
Statistical analysis
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.6384 · Mean difference (final values): 0.015 · 95% CI -0.049 to 0.08For Day 3
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.148 · Mean difference (final values): 0.046 · 95% CI -0.016 to 0.109For Day 7
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.4959 · Mean difference (final values): 0.026 · 95% CI -0.049 to 0.101For Day 14
SecondaryChange From Baseline to Post Baseline for Pre-BD FVC

Post baseline visits include Day 3, Day 7, Day 14, Day 28, Day 56, and Day 84.

Time frame:
From first IP dose to Day 84
Reported as:
Mean · Liter
Change From Baseline to Post Baseline for Pre-BD FVC
LiterBenra 30 mgPlacebo
Day 30.122 ± 0.2470.11 ± 0.267
Day 70.138 ± 0.2770.099 ± 0.292
Day 140.126 ± 0.3310.111 ± 0.312
Day 280.21 ± 0.3470.134 ± 0.34
Day 560.211 ± 0.4040.187 ± 0.369
Day 840.213 ± 0.3760.131 ± 0.359
Statistical analysis
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.8667 · Mean difference (final values): 0.006 · 95% CI -0.062 to 0.073For Day 3
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.2734 · Mean difference (final values): 0.041 · 95% CI -0.033 to 0.115For Day 7
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.7252 · Mean difference (final values): 0.015 · 95% CI -0.068 to 0.098For Day 14
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.0976 · Mean difference (final values): 0.075 · 95% CI -0.014 to 0.164For Day 28
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.6536 · Mean difference (final values): 0.023 · 95% CI -0.077 to 0.122For Day 56
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.0595 · Mean difference (final values): 0.092 · 95% CI -0.004 to 0.188For Day 84
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.1377 · Mean difference (final values): 0.063 · 95% CI -0.02 to 0.147For average of Day 28, 56, 84.
SecondaryPercentage of Pre-BD FEV1 Responder

Pre-BD FEV1 responder is defined as change from baseline in FEV1 \>=100 ml

Time frame:
From first IP dose to Day 84
Reported as:
Number · Percentage of Participants
Percentage of Pre-BD FEV1 Responder
Percentage of ParticipantsBenra 30 mgPlacebo
Day 348.237.4
Day 748.342.0
Day 1450.038.9
Day 2857.646.9
Day 5662.155.8
Day 8457.951.8
Statistical analysis
  • Benra 30 mg vs Placebo · Regression, Logistic · p = 0.1604 · Odds ratio (or): 1.49 · 95% CI 0.85 to 2.58For Day 3
  • Benra 30 mg vs Placebo · Regression, Logistic · p = 0.3400 · Odds ratio (or): 1.29 · 95% CI 0.76 to 2.19For Day 7
  • Benra 30 mg vs Placebo · Regression, Logistic · p = 0.0924 · Odds ratio (or): 1.58 · 95% CI 0.93 to 2.70For Day 14
  • Benra 30 mg vs Placebo · Regression, Logistic · p = 0.1052 · Odds ratio (or): 1.57 · 95% CI 0.91 to 2.71For Day 28
  • Benra 30 mg vs Placebo · Regression, Logistic · p = 0.3271 · Odds ratio (or): 1.30 · 95% CI 0.77 to 2.21For Day 56
  • Benra 30 mg vs Placebo · Regression, Logistic · p = 0.3017 · Odds ratio (or): 1.33 · 95% CI 0.77 to 2.29For Day 84
SecondaryChange From Baseline in ACQ-6

ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.

Time frame:
From first IP dose to Day 84
Reported as:
Mean · Score on a scale
Change From Baseline in ACQ-6
Score on a scaleBenra 30 mgPlacebo
Day 14-0.989 ± 0.901-0.665 ± 0.837
Day 28-1.126 ± 0.947-0.693 ± 0.869
Day 56-1.164 ± 1.132-0.827 ± 1.023
Day 84-1.355 ± 1.146-0.867 ± 1.114
Statistical analysis
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.0024 · Mean difference (final values): -0.293 · 95% CI -0.481 to -0.105For Day 14
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.0002 · Mean difference (final values): -0.402 · 95% CI -0.609 to -0.195For Day 28
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.0117 · Mean difference (final values): -0.312 · 95% CI -0.554 to -0.07For Day 56
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.0004 · Mean difference (final values): -0.472 · 95% CI -0.731 to -0.213For Day 84
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.0002 · Mean difference (final values): -0.395 · 95% CI -0.603 to -0.188For average of Day 28, 56, 84.
SecondaryChange From Baseline in St. George's Respiratory Questionnaire (SGRQ)

The SGRQ is designed to measure health impairment in patients with asthma and COPD. It contains two parts: Part 1 (Questions 1 to 8) covers the patients' recollection of their symptoms over a preceding 4 weeks; Part 2, 42 items, relates to the daily activity and psychosocial impacts of the individual's respiratory condition. Total score is presented as a percentage of overall impairment, in which 100 represents the worst possible health status, while 0 indicates the best.

Time frame:
From first IP dose to Day 84
Reported as:
Mean · Score on a scale
Change From Baseline in St. George's Respiratory Questionnaire (SGRQ)
Score on a scaleBenra 30 mgPlacebo
Day 28-16.956 ± 15.51-9.444 ± 14.136
Day 56-19.941 ± 21.528-13.802 ± 16.705
Day 84-23.343 ± 20.302-14.385 ± 18.836
Statistical analysis
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.0001 · Mean difference (final values): -7.229 · 95% CI -10.832 to -3.626For Day 28
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.0115 · Mean difference (final values): -5.942 · 95% CI -10.538 to -1.346For Day 56
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.0004 · Mean difference (final values): -8.599 · 95% CI -13.3 to -3.898For Day 84
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.0003 · Mean difference (final values): -7.257 · 95% CI -11.133 to -3.38For average of Day 28, 56, 84.
SecondaryChange From Baseline to End of Treatment in FeNO

Airway inflammation was evaluated via fractional exhaled nitric oxide (FeNO) measurement.

Time frame:
From first IP dose to Day 84
Reported as:
Mean · ppb
Change From Baseline to End of Treatment in FeNO
ppbBenra 30 mgPlacebo
Change From Baseline to End of Treatment in FeNO5.92 ± 45.2950.05 ± 27.634
Statistical analysis
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.2825 · Mean difference (final values): 5.414 · 95% CI -4.492 to 15.321Model includes covariates of treatment, baseline FeNO value, region, visit, treatment by visit interaction.
SecondaryChange From Baseline to End of Treatment in Total Lung Capacity (TLC) for Sub-study Patients

Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.

Time frame:
From first IP dose to Day 84
Reported as:
Mean · Liter
Change From Baseline to End of Treatment in Total Lung Capacity (TLC) for Sub-study Patients
LiterBenra 30 mgPlacebo
Change From Baseline to End of Treatment in Total Lung Capacity (TLC) for Sub-study Patients-0.276 ± 0.677-0.175 ± 0.418
SecondaryChange From Baseline to End of Treatment in Ratio of Residual Volume (RV) and Total Lung Capacity (TLC) for Sub-study Patients

Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.

Time frame:
From first IP dose to Day 84
Reported as:
Mean · ratio
Change From Baseline to End of Treatment in Ratio of Residual Volume (RV) and Total Lung Capacity (TLC) for Sub-study Patients
ratioBenra 30 mgPlacebo
Change From Baseline to End of Treatment in Ratio of Residual Volume (RV) and Total Lung Capacity (TLC) for Sub-study Patients-0.05 ± 0.056-0.026 ± 0.087
SecondaryChange From Baseline to End of Treatment in Inspiratory Capacity (IC) for Sub-study Patients

Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.

Time frame:
From first IP dose to Day 84
Reported as:
Mean · Liter
Change From Baseline to End of Treatment in Inspiratory Capacity (IC) for Sub-study Patients
LiterBenra 30 mgPlacebo
Change From Baseline to End of Treatment in Inspiratory Capacity (IC) for Sub-study Patients0.119 ± 0.447-0.268 ± 0.603
SecondaryChange From Baseline to End of Treatment in Functional Residual Capacity (FRC) for Sub-study Patients

Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.

Time frame:
From first IP dose to Day 84
Reported as:
Mean · Liter
Change From Baseline to End of Treatment in Functional Residual Capacity (FRC) for Sub-study Patients
LiterBenra 30 mgPlacebo
Change From Baseline to End of Treatment in Functional Residual Capacity (FRC) for Sub-study Patients-0.394 ± 0.7830.093 ± 0.466
SecondaryChange From Baseline to End of Treatment in Vital Capacity (VC) for Sub-study Patients

Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.

Time frame:
From first IP dose to Day 84
Reported as:
Mean · Liter
Change From Baseline to End of Treatment in Vital Capacity (VC) for Sub-study Patients
LiterBenra 30 mgPlacebo
Change From Baseline to End of Treatment in Vital Capacity (VC) for Sub-study Patients0.139 ± 0.2450.033 ± 0.676
SecondaryDuration of IP Administration

Duration of IP administration is last IP dose date - first IP dose +1.

Time frame:
From first IP to last IP
Reported as:
Mean · Days
Duration of IP Administration
DaysBenra 30 mgPlacebo
Duration of IP Administration55.9 ± 7.8356.2 ± 7.61
Other pre-specifiedSerum Concentration of Benralizumab

PK sample was collected pre-dose at each visit

Time frame:
From first dose to end of treatment period (Day 84)
Reported as:
Geometric mean · ng/mL
Serum Concentration of Benralizumab
ng/mLBenra 30 mg
Baseline1.95 ± NA
Day 31266.78 ± 199.59
Day 71449.47 ± 125.02
Day 141317.92 ± 79.53
Day 28738.47 ± 80.77
Day 561015.72 ± 59.74
Day 841079.22 ± 73.24
Other pre-specifiedPK Parameter of Benralizumab (Cmax)

PK parameters are derived in patients with at least three qualifiable serum PK concentrations post first dose (collected on Day 3, 7, and either 14, or 28)

Time frame:
First IP dose cycle (ie, data collected on Days 3, 7, 14 and 28)
Reported as:
Geometric mean · ng/mL
PK Parameter of Benralizumab (Cmax)
ng/mLBenra 30 mg
PK Parameter of Benralizumab (Cmax)1729.6 ± 36.8
Other pre-specifiedAnti-drug Antibody Responses

Anti-drug antibody responses at baseline and post baseline, including nAb responses

Time frame:
From first IP dose to end of treatment period (Day 84)
Reported as:
Count of participants · Participants
Anti-drug Antibody Responses
ParticipantsBenra 30 mgPlacebo
ADA prevalence72
nAb prevalence20
Both baseline and post baseline positive12
Only post baseline positive50
Only baseline positive10
Other pre-specifiedChange From Baseline to End of Treatment in PGI-S

The patient global impression of severity (PGI-S) is a single item designed to capture the patient's perception of overall symptom severity at the time of the completion using a 6-point categorical response scale (no symptom \[0\] to very severe symptom \[5\])

Time frame:
From first IP dose to Day 84
Reported as:
Mean · Score on a scale
Change From Baseline to End of Treatment in PGI-S
Score on a scaleBenra 30 mgPlacebo
Change From Baseline to End of Treatment in PGI-S-1.2 ± 1.31-0.8 ± 1.21
Statistical analysis
  • Benra 30 mg vs Placebo · Mixed Models Analysis · p = 0.0120 · Mean difference (final values): -0.365 · 95% CI -0.649 to -0.081For Day 84
Other pre-specifiedChange From Baseline to End of Treatment in CGI-C

Clinician global impression of change (CGI-C) is used for an overall evaluation of response to treatment. The investigator is asked to rate the degree of change in overall asthma status compare to the start of treatment. A 7-point rating scale is used from 1=very much improved to 7=very much worse.

Time frame:
From first IP dose to Day 84
Reported as:
Count of participants · Participants
Change From Baseline to End of Treatment in CGI-C
ParticipantsBenra 30 mgPlacebo
Very much improved1810
Much improved3936
Minimally improved3928
No change1728
Minimally worse07
Much worse01
Very much worse00
Missing55
Statistical analysis
  • Benra 30 mg vs Placebo · Regression, Logistic · p = 0.0018 · Odds ratio (or): 2.97 · 95% CI 1.50 to 5.88For Day 84
Other pre-specifiedChange From Baseline to End of Treatment in PGI-C

Patient global impression of change (PGI-C) is used for an overall evaluation of response to treatment. The patient is asked to rate the degree of change in overall asthma status compare to the start of treatment. A 7-point rating scale is used from 1=very much improved to 7=very much worse.

Time frame:
From first IP dose to Day 84
Reported as:
Count of participants · Participants
Change From Baseline to End of Treatment in PGI-C
ParticipantsBenra 30 mgPlacebo
Very much improved3217
Much improved4235
Minimally improved2329
No change1427
Minimally worse14
Much worse11
Very much worse10
Missing42
Statistical analysis
  • Benra 30 mg vs Placebo · Regression, Logistic · p = 0.0107 · Odds ratio (or): 2.51 · 95% CI 1.24 to 5.09For Day 84
Other pre-specifiedChange From Baseline to End of Treatment in Specific Airway Resistance (SGaw) for Sub-study Patients

Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.

Time frame:
From first IP dose to Day 84
Reported as:
Mean · 1/(kPa*sec)
Change From Baseline to End of Treatment in Specific Airway Resistance (SGaw) for Sub-study Patients
1/(kPa*sec)Benra 30 mgPlacebo
Change From Baseline to End of Treatment in Specific Airway Resistance (SGaw) for Sub-study Patients-0.05 ± 0.1460.052 ± 0.224
Other pre-specifiedChange From Baseline to End of Treatment in Airway Resistance (Raw) for Sub-study Patients

Lung volume subdivisions include total lung capacity (TLC), residual volume (RV), vital capacity (VC), functional residual capacity (FRC), and inspiratory capacity (IC), as well as airway resistance (Raw and SGaw) measurements.

Time frame:
From first IP dose to Day 84
Reported as:
Mean · kPa/L/sec
Change From Baseline to End of Treatment in Airway Resistance (Raw) for Sub-study Patients
kPa/L/secBenra 30 mgPlacebo
Change From Baseline to End of Treatment in Airway Resistance (Raw) for Sub-study Patients-0.233 ± 1.509-0.2 ± 0.532

Adverse events

Collected over From informed consent form was signed to end of study (ie, Day 112 follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benra 30 mg0/118 (0%)1/118 (0.8%)28/118 (23.7%)
Placebo0/115 (0%)7/115 (6.1%)30/115 (26.1%)
Most frequent serious events
Most frequent serious events
EventBenra 30 mgPlacebo
PneumoniaInfections and infestations0/1182/115
AsthmaRespiratory, thoracic and mediastinal disorders0/1182/115
Coronary artery diseaseCardiac disorders0/1181/115
Lower respiratory tract infectionInfections and infestations0/1181/115
Generalised tonic-clonic seizureNervous system disorders0/1181/115
MigraineNervous system disorders0/1181/115
Drug hypersensitivityImmune system disorders1/1180/115
Most frequent other events
Most frequent other events
EventBenra 30 mgPlacebo
AsthmaRespiratory, thoracic and mediastinal disorders11/11818/115
NasopharyngitisInfections and infestations8/1186/115
Upper respiratory tract infectionInfections and infestations6/1186/115
BronchitisInfections and infestations6/1183/115

Baseline characteristics

Age, Continuous
Age, Continuous(years)Benra 30 mgPlaceboTotal
Mean51.9 ± 13.6250.9 ± 12.3451.4 ± 12.99
Sex: Female, Male
Sex: Female, Male(Participants)Benra 30 mgPlaceboTotal
Female7483157
Male443276
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Benra 30 mgPlaceboTotal
White6967136
Black or African American347
Asian394079
Other7411
08

Study locations

54 sites
  • Research Site
    Scottsboro, Alabama 35768, United States
  • Research Site
    Gilbert, Arizona 85234, United States
  • Research Site
    Denver, Colorado 80206, United States
  • Research Site
    Miami, Florida 33174, United States
  • Research Site
    Tampa, Florida 33607, United States
  • Research Site
    Vero Beach, Florida 32960, United States
  • Research Site
    Winter Park, Florida 32789, United States
  • Research Site
    Fort Mitchell, Kentucky 41017, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Cincinnati, Ohio 45231, United States
  • Research Site
    Oklahoma City, Oklahoma 73103, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    Philadelphia, Pennsylvania 19140, United States
  • Research Site
    Lampasas, Texas 76550, United States
  • Research Site
    McKinney, Texas 75069, United States
  • Research Site
    Curico, 3341643, Chile
  • Research Site
    Santiago, 404366, Chile
  • Research Site
    Santiago, 7500692, Chile
  • Research Site
    Santiago, 7750495, Chile
  • Research Site
    Bamberg, 96049, Germany
  • Research Site
    Darmstadt, 64283, Germany
  • Research Site
    Frankfurt am Main, 60389, Germany
  • Research Site
    Frankfurt am Main, 60596, Germany
  • Research Site
    Frankfurt, 60596, Germany
  • Research Site
    Hamburg, 20354, Germany
  • Research Site
    Hamburg, 22299, Germany
  • Research Site
    Hannover, 30167, Germany
  • Research Site
    Hannover, 30625, Germany
  • Research Site
    Hannover, D-30173, Germany
  • Research Site
    Mainz, 55131, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Balassagyarmat, 2660, Hungary
  • Research Site
    Edelény, 3780, Hungary
  • Research Site
    Farkasgyepü, 8582, Hungary
  • Research Site
    Gödöllő, 2100, Hungary
  • Research Site
    Hajdúnánás, 4080, Hungary
  • Research Site
    Komárom, 2900, Hungary
  • Research Site
    Miskolc, 3529, Hungary
  • Research Site
    Pécs, 7626, Hungary
  • Research Site
    Pécs, 7635, Hungary
  • Research Site
    Cheongju-si, 28644, Korea, Republic of
  • Research Site
    Daegu, 42415, Korea, Republic of
  • Research Site
    Jeonju-si, 54907, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 03312, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 05505, Korea, Republic of
  • Research Site
    Seoul, 06351, Korea, Republic of
  • Research Site
    Seoul, 06591, Korea, Republic of
  • Research Site
    Iloilo City, 5000, Philippines
  • Research Site
    Lipa City, Philippines
  • Research Site
    Manila, 1000, Philippines
  • Research Site
    Quezon City, 0870, Philippines
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Aug 2018, 20 months.

Results were first posted in Oct 2019, 1 year 2 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 20 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2016
First posted
Aug 17, 2016
StartActual
Nov 9, 2016
Primary completionActual
Aug 1, 2018
CompletionActual
Aug 1, 2018
Results first posted
Oct 7, 2019
Last update
Oct 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02869438
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 17, 2016
Start date
Nov 9, 2016
Primary completion
Aug 1, 2018
Completion
Aug 1, 2018
Results posted
Oct 7, 2019
Last update
Oct 29, 2019

Study contacts

Reynold A Panettieri, Doctor of Medicine
principal investigator · Child Health Institute of NJ, 89 French Street, Suite 4210, New Brunswick, NJ, 08901, USA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion